Tadalafil Lilly ICOS.

Article Details

Citation

Copy to clipboard

Rotella DP

Tadalafil Lilly ICOS.

Curr Opin Investig Drugs. 2003 Jan;4(1):60-5.

PubMed ID

12625031 [ View in PubMed

]

Abstract

Tadalafil is a phosphodiesterase type 5 inhibitor in development by Lilly ICOS for the potential treatment of erectile dysfunction. The compound will be marketed in North America and Europe by a collaboration formed by Eli Lilly & Co and ICOS Corp. Eli Lilly & Co has marketing rights in all other territories. Marketing approval in Europe was granted in November 2002, with launch expected in the first half of 2003. An approvable letter was issued by the FDA in April 2002, with a US launch anticipated in the first half of 2003.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tadalafil	cGMP-specific 3',5'-cyclic phosphodiesterase	Protein	Humans	Yes	Inhibitor	Details